CSL Ltd shares have climbed into the green in Thursday lunchtime trade. The ASX biotech shares are up around 1% and are changing hands for $176.50 each.
The shares have now jumped about 31% over the past month alone after rebounding strongly in August following the company's FY26 results announcement.
CSL reported total revenue of US$15.8 billion and NPAT of US$2.6 billion. The result came in way ahead of guidance and CSL management described FY26 as a 'reset year', with FY27 marking a return to growth.
A sectorwide rotation back into ASX healthcare shares has also helped boost CSL shares higher recently.
CSL is operating in a high-growth market, and its blood plasma division dominates the market for blood disorders and immunoglobulin products.
Market Index data shows the majority have a buy rating on CSL shares.
The past month has seen CSL go from strength to strength, and the share price rebound is impressive.
Telix Pharmaceuticals Ltd is a little different from CSL. The two businesses are Australian biotech companies but have a different focus, scale, and market position.
CSL focuses on plasma therapies while Telix focuses on radiopharmaceuticals.
Its shares are in the spotlight this week after the company announced that its brain cancer imaging drug, Pixclara, has received approval from the US FDA.
The average $25.48 target price implies a potential 45% upside, while the maximum $30.99 target price suggests the stock could climb 76%.